Otsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) recently announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease […]
HistoSonics Announces USD 250mn Financing Growth
HistoSonics, Inc., one of the developers of the Edison Histotripsy System and novel histotripsy therapy platform, recently announced the closing of an oversubscribed USD 250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison […]